ORIC Pharmaceuticals Q3 2021 Earnings Report
Key Takeaways
ORIC Pharmaceuticals reported its Q3 2021 financial results, highlighting the advancement of its pipeline, including initial clinical data from the ORIC-101 Phase 1b trial and preclinical data on ORIC-114. The company's cash and investments of $296.5 million are expected to fund operations into 2024.
Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide was presented at AACR-NCI-EORTC.
Preclinical data on ORIC-114 was presented at AACR-NCI-EORTC.
An update on the oral CD73 inhibitor program will be presented at the American Society of Hematology (ASH) Annual Meeting.
Phase 1 trial initiation of single agent ORIC-533 in patients with multiple myeloma is expected in 4Q 2021.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC anticipates several milestones in the fourth quarter of 2021.
Positive Outlook
- Present update on oral CD73 inhibitor program at the ASH Annual Meeting
- Initiate single agent Phase 1 trial in patients with multiple myeloma (ORIC-533)
- File IND for ORIC-944
- CTA filing submitted for ORIC-114
- IND filing for ORIC-944 expected in 4Q 2021